MaaT Pharma Reports Strong Final Phase 1b Data of MaaT033 in ALS Patients
Details : MaaT033, a standardized, donor-derived, high-richness, high-diversity oral Microbiome Ecosystem Therapy containing anti-inflammatory ButycoreTM species.
Product Name : MaaT033
Product Type : Probiotic
Upfront Cash : Inapplicable
May 12, 2025
MaaT Pharma Announces Positive Phase 1b Results for MaaT033 in ALS
Details : MaaT033 is a an oral, donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapy. It is being evaluated for the treatment of amyotrophic lateral sclerosis.
Product Name : MaaT033
Product Type : Probiotic
Upfront Cash : Inapplicable
November 26, 2024
Lead Product(s) : Stiripentol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocodex Develops DIACOMIT® Oral Suspension for Dravet Syndrome in Children
Details : Diacomit (stiripentol) a GABA-A receptor inhibitor oral suspension, a new formulation is being investigated to aid in the treatment of dravet syndrome in young children.
Product Name : Diacomit
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2024
Lead Product(s) : Stiripentol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Crossject announces highly successful closing of its €8 million rights offering
Details : The net proceeds will be used to support Crossject’s activities in bringing its Zepizure (midazolam), a short-acting hypnotic-sedative epileptic rescue therapy, to market.
Product Name : Zepizure
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 06, 2024
MaaT Pharma Gets Positive DSMB Review for MaaT033 in ALS Trial
Details : MaaT033 is an oral, donor-derived microbiome therapy containing Butycore, being evaluated for ambulatory use in treating amyotrophic lateral sclerosis.
Product Name : MaaT033
Product Type : Probiotic
Upfront Cash : Inapplicable
February 29, 2024
Crossject Obtains a Financing up To ‚¬12 Million, in Two Tranches
Details : The financing aims to support the clinical development of Zepizure (midazolam), a short-acting hypnotic-sedative medication currently undergoing evaluation in patients for epileptic seizures.
Product Name : Zepizure
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 27, 2024
Crossject Signs a Geographic Extension of ZEPIZURE® Commercialization Agreement in Europe
Details : Under the terms of the agreement, Crossject Zepizure (midazolam) will be commercialized in the European market for the treatment of epileptic seizures.
Product Name : Zepizure
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 05, 2024
Details : MaaT033 is an allo-HCT, oral, donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapies, for ambulatory use, containing Butycore , a group of bacterial species known to produce anti-inflammatory short-chain-fatty acid.
Product Name : MaaT033
Product Type : Probiotic
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AlgoTx’s ATX01 Granted Fast Track Designation by FDA for Chemotherapy-Induced Neuropathic Pain
Details : ATX01 is a novel and patented topical formulation of amitriptyline. Its non-systemic mode of action locally inhibits pain signaling by the skin’s nerve fibers whilst minimizing systemic penetration, thus avoiding unwanted toxicity.
Product Name : ATX01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATX01, an innovative topical treatment for the pain of peripheral neuropathy successfully reached its safety and pharmacokinetics objectives in Phase I trial, clearing the way for Phase II development in Chemotherapy-Induced Peripheral Neuropathy.
Product Name : ATX01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2021
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable